Plasma Metabolite Profile for Memory Impairment Risk Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting early risk of memory impairment, such as Alzheimer's disease, are invasive, time-consuming, expensive, and lack sensitivity and specificity, particularly in preclinical stages, necessitating the development of more accurate and minimally invasive biomarkers.
Innovation Solution
Analyzing a subject's plasma metabolite profile and comparing it to a normal profile to identify changes indicative of an increased risk of memory impairment, using a combination of metabolite analysis and statistical models to generate a Preclinical Alzheimer's Disease Index (PADI) for risk assessment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If invasive methods (lumbar puncture, brain imaging) are used to detect early Alzheimer's risk, then diagnostic accuracy is improved, but patient comfort and accessibility deteriorate
Solution Approach 1:
The patent extracts the diagnostic function from invasive procedures (lumbar puncture, brain imaging) and relocates it to a blood-based metabolite profile analysis. By measuring metabolite levels in peripheral blood samples, the system achieves early Alzheimer's detection without requiring invasive access to the central nervous system, thus maintaining diagnostic accuracy while dramatically improving patient comfort and accessibility
Solution Approach 2:
The patent introduces blood-based metabolite profiles as an intermediary marker that correlates with brain pathology. Instead of directly measuring brain amyloid or tau, the system uses peripheral blood metabolites as a surrogate indicator, enabling non-invasive detection of Alzheimer's risk while preserving diagnostic utility
2Measurement precision
If comprehensive brain imaging protocols are used to detect preclinical Alzheimer's, then detection sensitivity is improved, but time consumption and cost deteriorate
Solution Approach 1:
The patent extracts the essential diagnostic information from complex, time-consuming brain imaging protocols and concentrates it into a simplified blood-based metabolite profile analysis. By focusing on specific metabolite markers in peripheral blood, the system achieves comparable detection sensitivity for preclinical Alzheimer's without requiring hours of scanner time, thus dramatically reducing the time and resource investment needed for screening
Solution Approach 2:
The patent replaces expensive, resource-intensive brain imaging procedures with a low-cost, rapid blood metabolite analysis. The metabolite profile assessment requires minimal laboratory resources and can be processed quickly, making it a scalable screening tool that avoids the high costs and long wait times associated with comprehensive neuroimaging protocols
3Ease of operation
If blood-based biomarkers are used for preclinical Alzheimer's detection, then accessibility and cost are improved, but sensitivity and specificity deteriorate
Solution Approach 1:
The patent segments the complex diagnostic challenge into distinct metabolite markers, each associated with specific pathological processes in Alzheimer's disease. By identifying and measuring individual metabolite levels (such as those related to energy metabolism, inflammation, and oxidative stress), the system builds a composite profile that achieves high sensitivity and specificity for preclinical detection, overcoming the limitations of single-marker approaches
Solution Approach 2:
The patent combines multiple metabolite measurements into an integrated blood-based biomarker profile, analogous to creating a composite material with enhanced properties. The metabolite profile integrates information from various metabolic pathways, producing a composite diagnostic indicator that achieves superior sensitivity and specificity compared to any single metabolite measure alone, while maintaining the accessibility and low cost of blood sampling
Data Source
AI summary
The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.